BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials in more than 260 posters and presentations, including more than 65 oral presentations evaluating Celgene products in blood cancers at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida from December 4-7.
